Navigation Links
Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
Date:6/5/2010

CHICAGO - Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

The findings were presented at the 46th Annual Meeting of the American Society of Clinical Oncology today, and published in the New England Journal of Medicine. Hagop Kantarjian, M.D., professor and chair of MD Anderson's Department of Leukemia, presented the findings and is the corresponding author on the published study.

Currently, imatinib, or Gleevec , is the approved initial therapy for CML, which has increased the five-year survival rate for the disease from 50 percent to 90 percent, said Kantarjian. However, 30-40 percent of imatinib patients do not achieve confirmed cytogenic complete response (CCyR), or the absence of the defective chromosome that causes the disease, within a year. This benchmark is clearly associated with improvements in long-term outcome, said Kantarjian.

"Previous research conducted at MD Anderson found that more patients taking dasatinib were achieving complete responses more quickly than they do on the current standard of care," said Kantarjian. "In this pivotal Phase III study, we confirmed that dasatinib gets more patients to high-quality remission faster than imatinib, making it a superior front-line therapy. Dasatinib, on average, also has a more favorable side-effect profile."

For the multinational Phase III study, known as DASSIN (Dasatinib versus Imatinib Study In treatment-nave CML patients), 519 newly diagnosed CML patients who had received no prior treatment were randomized to receive either dasatinib, also known as Sprycel , 100 milligrams once daily (259 patients), or imatinib, 400 milligrams once daily (260 patients). CCyR, confirmed on two assessments, was the study's primary endpoint. Secondary endpoints included rate of and times to CCyR and major molecular response (MMR), defined as a level of .1 percent or lower of the defective chromosome, as well as safety.

After a minimum follow-up of 12 months, the researchers found that the rates of confirmed CCyR and MMR in those taking dasatinib were 77 percent and 46 percent, respectively, compared to 66 percent and 28 percent, on the imatinib arm.

Therapy failed in nine patients (3.5 percent) in those taking imatinib, compared to five patients (1.9 percent) taking dasatanib. The dasatanib arm reported fewer side effects - nausea, vomiting, muscle inflammation, rash, fluid retention - with most other toxicities being similar in both arms.

"We've learned that in cancer therapy, it's important to use your big guns up front. We know that achieving complete cytogenetic response within a year of starting treatment is associated with more favorable long-term survival; therefore, using this second-generation drug first will likely improve outcomes for patients with chronic myeloid leukemia," said Kantarjian.

CML is caused by an abnormality known as the Philadelphia chromosome that produces an aberrant protein, Bcr-Abl, which causes the overproduction of one type of white blood cell that drives the disease. Dasatinib, a tyrosine kinase inhibitor, blocks the action of Bcr-Abl; the drug is currently approved by the U.S. Food and Drug Administration for patients who can't tolerate imatinib or whose CML resists the drug.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Second-line CML drugs evoke faster response than front-line therapy
2. Patient age not a factor in use of second-line therapy for lung cancer
3. Cost of Psoriasis Drugs Rising Faster Than Others
4. Faster Heart Rate May Raise Risk of Heart Attack Death
5. Blacks with MS have more severe symptoms, decline faster than whites, new study shows
6. Second Language Comes Faster When Taught in Own Accent
7. 'Get Pregnant' Aims To Help Couples Conceive Naturally, Faster
8. Minimally invasive sports hernia repair may get athletes back in the game faster, study says
9. SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less?
10. Cognition declines 4 times faster in people with Alzheimers disease than those with no dementia
11. Alterian Releases Professional Edition of its Content Manager Technology, Offering Partners and Clients an Even Faster Time-to-Live for Their Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series ... 2016. Each webinar features a dynamic expert and thoughtful presentation to give attendees ... and facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... Tenn. (PRWEB) , ... February 10, 2016 , ... ... the American Academy of Emergency Medicine , an emergency medicine professional ... practice management services . , The American Academy of Emergency Medicine, or ...
(Date:2/10/2016)... ... 10, 2016 , ... The Wickman Agency in Garland, TX ... local community. Pledging to select a new beneficiary every 60 days, the agency ... goal is to bring community awareness to important local causes by forming campaigns ...
(Date:2/10/2016)... , ... February 10, 2016 , ... 10 Best ... There were three leading bottled water brand owners that topped the list as a ... connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch water ...
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- QT Vascular Ltd., together with its subsidiaries (the ... subsidiaries, the "Group"), is pleased to provide an ... ("ÄngioScore") (now owned by Spectranetics Corporation (NASDAQ: ... States Court of Appeals for the ... district court order (the "DCO").   The DCO had ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , Feb. 10, 2016 CSI Specialty Group ... the launch of the Specialty Pharmacy Podcast. A free, ... aimed at providing real-world education, discussion and context amongst ... --> --> The Specialty Pharmacy ... of CSI Specialty Group Suzette DiMascio, CHE, CMCE, CPC, ...
Breaking Medicine Technology: